

---

**Product Data Sheet**

---

Product Name: UMB-32  
Cat. No.: GC14168

**Chemical Properties**

Cas. No. 1635437-39-6

Chemical Name N-(1,1-dimethylethyl)-2-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-imidazo[1,2-a]pyrazin-3-amine

SMILES CC(C)(C)NC1=C(N=C2N1C=CN=C2)C3=CC=C(C4=C(C)ON=C4C)C=C3

Formula  $C_{21}H_{23}N_5O$  M.Wt 361.4

Solubility  $\leq 20$ mg/ml in ethanol; 10mg/ml in DMSO; 20mg/ml in dimethyl formamide Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

**Background**

UMB-32 is a potent, selective inhibitor of the BET bromodomain BRD4 [1]. The BET family (BRD2, BRD3, BRD4, and BRDT) functions as transcriptional coactivator proteins. BET bromodomains are also important mediators of cell cycle progression and facilitate developmental transitions such as spermiogenesis. Deregulation of BET bromodomain function has been observed in numerous malignancies. BET bromodomain inhibition has contributed new insights into gene regulation and emerged as a promising therapeutic strategy in cancer [1].

In vitro: UMB-32 bound to BRD4 with a  $K_d$  value of 550 nM and 724 nM cellular potency in BRD4-dependent lines. UMB-32 showed potency against TAF1, a bromodomain-containing transcription factor. UMB-32 showed markedly increased potency for the BET proteins associated with a dramatic improvement in selectivity. UMB-32 potently bound to the TAF1 and TAF1L with the  $K_d$  values of 560nM and 1.3  $\mu$ M, respectively [1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

Reference:

[1] McKeown M R, Shaw D L, Fu H, et al. Biased multicomponent reactions to develop novel bromodomain inhibitors[J]. Journal of medicinal chemistry, 2014, 57(21): 9019-9027.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**